Astrana Health vs FTI Consulting
ASTH and FCN side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASTH and FCN compare
FTI Consulting is the larger company, worth 3.1 times as much as Astrana Health ($5.6B against $1.8B).
On earnings, FTI Consulting is cheaper: it trades at 25.6× trailing earnings, against 39.0× for Astrana Health.
Astrana Health grew revenue faster over the last twelve months (58.9% versus 7.8% for FTI Consulting).
FTI Consulting keeps more of each dollar of sales as profit, with a net margin of 5.9% compared with 1.1% at Astrana Health.
FTI Consulting scores higher on the StockData Score (11 against 8 for Astrana Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASTH | FCN |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $5.6B |
| Share price | $31.99 | $205.53 |
| Change, 1 year | 48.6% | 24.6% |
| Change, 5 years | −66.2% | 40.3% |
| Beta (5Y) | 1.04 | −0.58 |
| Employees | 3,000 | 8,118 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 4 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 39.0× | 25.6× (better) |
| P/S | 0.5× (better) | 1.4× |
| P/B | 2.1× (better) | 4.2× |
| EV/EBITDA | 14.2× (better) | 15.8× |
| P/FCF | 18.9× | 15.8× (better) |
| PEG | – | 3.29 |
| FCF yield | 5.3% | 6.3% (better) |
| Fair value | $26.18 | $170.62 |
| Margin of safety | −22.2% | −20.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 58.9% (better) | 7.8% |
| Revenue growth, 5Y average | 35.9% (better) | 9.0% |
| Net income growth (TTM) | 60.5% (better) | −12.3% |
| EPS growth (TTM) | 57.7% (better) | 2.0% |
| EPS growth, 5Y average | −14.6% | 7.8% (better) |
| Profitability | ||
| Gross margin | 10.5% | 32.2% (better) |
| Operating margin | 2.6% | 8.8% (better) |
| Net margin | 1.1% | 5.9% (better) |
| FCF margin | 2.5% | 8.9% (better) |
| Return on equity | 5.1% | 15.2% (better) |
| Return on invested capital | 6.0% | 12.4% (better) |
| Financial health | ||
| Debt / equity | 1.13 | 0.64 (better) |
| Net debt / EBITDA | 3.28 | 1.90 (better) |
| Interest coverage | 1.5× | 9.0× (better) |
| Current ratio | 1.23 | 1.72 (better) |
| Altman Z-score | 2.77 | 3.88 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Payout ratio | 4.6% | – |
| Buyback yield | 1.00% | 12.4% (better) |
| Shareholder yield | 1.00% | 12.4% (better) |
| Ownership | ||
| Held by institutions | 57.7% | 112% |
| Held by insiders | 30.7% | 2.5% |
| Insider net buying, 12 months | – | −$342K |
| Short interest, % of float | 7.8% | 9.9% |
Go deeper
- ASTH stock overview
- ASTH income statement
- ASTH valuation and score
- FCN stock overview
- FCN income statement
- FCN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.